top of page

Unlock Your NMIBC Pathology Report: What Those Codes Really Mean for You

  • Writer: Polygon Health Team
    Polygon Health Team
  • May 4
  • 8 min read

After your procedure (TURBT), you get a pathology report. It's packed with terms like 'Ta,' 'T1,' 'CIS,' 'Low Grade,' 'High Grade' – it can feel like reading a foreign language when you're already stressed. Let's break down what these crucial pieces of information mean and why they matter significantly for your treatment journey.



The "T Stage" - How Deep Did it Go?


Your pathology report's "T stage" indicates how deeply the cancer has penetrated into your bladder's tissue layers. This information is critical because deeper invasion generally correlates with higher risks and different treatment approaches (Babjuk et al., 2023).


Ta: Staying on the Surface


When your report shows "Ta," this means the tumor is confined to the very innermost lining of your bladder (the urothelium). Think of it like a growth on the top layer of wallpaper in your home – it's visible and present, but hasn't penetrated deeper structures.

Ta tumors typically have a papillary appearance, meaning they grow outward in finger-like projections into the hollow center of your bladder. While they're growing inward toward the bladder space, they haven't broken through the basement membrane (the critical boundary between the urothelium and deeper tissues) (Humphrey et al., 2022).


T1: One Layer Deeper


A "T1" designation indicates the cancer has grown slightly deeper, breaking through the basement membrane and invading the lamina propria – the connective tissue layer just beneath the urothelium. Using our wallpaper analogy, the cancer has now penetrated into the wallpaper glue or adhesive layer.

This deeper invasion is significant because it means cancer cells have overcome an important tissue boundary, potentially giving them access to blood vessels and lymphatic channels. However, T1 tumors still have not reached the bladder's muscle layer (muscularis propria), which is why they remain classified as "non-muscle invasive" (Patel et al., 2020).


CIS (Carcinoma in Situ): The Deceptive Threat


CIS represents a unique category in bladder cancer. Unlike the more common papillary tumors that grow outward like small fingers or cauliflower, CIS appears as a flat, often reddened area on the bladder lining. It might be invisible to the naked eye or appear as a subtle inflammation.


What makes CIS particularly concerning is that while it remains confined to the surface layer (like Ta), it consists of highly abnormal, aggressive cells. Pathologists always classify CIS as "high grade" because these cells show significant abnormalities and have a higher risk of eventually invading deeper tissues if left untreated (Sylvester et al., 2021).

CIS can occur alone or alongside other tumor types and requires particular attention as it sometimes responds differently to treatments (Kamat et al., 2021).

Show Image Figure: Illustration showing bladder wall layers and where Ta, T1, and CIS tumors are located.



The "Grade" - How Aggressive Do the Cells Look?


While the T stage tells us how deep the cancer has grown, the grade tells us how the cancer cells look under the microscope – essentially, how abnormal or aggressive they appear. This information helps predict tumor behavior (Compérat et al., 2023).


Low Grade: More Resemblance to Normal Cells

Low-grade cancer cells retain some similarity to normal urothelial cells. They're more organized, with less variation in their shape, size, and arrangement. Under the microscope, they look more like the healthy cells from which they originated.

These tumors typically:

  • Grow more slowly

  • Are less likely to invade deeper tissues

  • Have a lower risk of progression to muscle-invasive disease

  • However, they can and often do recur, requiring ongoing surveillance


Low-grade tumors are often associated with better long-term outcomes, though they still require careful monitoring due to their tendency to return (Knowles & Hurst, 2022).


High Grade: More Abnormal and Aggressive

High-grade cancer cells look dramatically different from normal cells. They show substantial variations in size and shape, with abnormal nuclei and disorganized growth patterns. These cellular abnormalities reflect genetic changes that drive more aggressive behavior.

High-grade tumors generally:

  • Grow more rapidly

  • Have greater potential to invade deeper tissues

  • Are more likely to progress to muscle-invasive disease

  • Have higher recurrence rates

  • Require more aggressive treatment approaches (Robertson et al., 2022)


It's important to note that CIS is always classified as high grade due to the significant cellular abnormalities present, even though it's confined to the surface layer (Babjuk et al., 2023).



Putting It Together: Why Stage and Grade Matter So Much


The combination of stage and grade creates a more complete picture of your specific bladder cancer and guides treatment decisions. Let's look at some common combinations and what they typically mean:


Ta Low Grade

This combination represents the lowest risk category of NMIBC. These tumors have favorable characteristics: they're confined to the surface layer and show less aggressive cellular features. Treatment might include:

  • TURBT (surgical removal) followed by careful monitoring

  • Possibly a single instillation of chemotherapy in the bladder after TURBT

  • Less frequent follow-up cystoscopies compared to higher-risk categories (Sylvester et al., 2020)


Ta High Grade

Though still confined to the surface layer, the high-grade designation indicates more aggressive cellular features. These tumors warrant:

  • More aggressive surveillance

  • Possible intravesical therapy (medication placed directly into the bladder)

  • Closer monitoring for recurrence and progression (Chang et al., 2022)


T1 Low Grade

This combination is relatively uncommon. The invasion beyond the basement membrane (T1) suggests more aggressive behavior, even though the cells appear relatively well-differentiated. These cases often require:

  • Careful pathologic review (sometimes a second opinion)

  • Consideration of intravesical therapy

  • Close surveillance (Compérat et al., 2023)


T1 High Grade

This represents a high-risk NMIBC category. The combination of deeper invasion and aggressive cellular features correlates with greater risks of both recurrence and progression to muscle-invasive disease. Management typically involves:

  • Consideration of a repeat TURBT to ensure complete removal and accurate staging

  • Course of intravesical BCG immunotherapy

  • More frequent follow-up cystoscopies

  • In some cases, particularly with additional risk factors, early consideration of more aggressive treatments (Kamat et al., 2021; Ferro et al., 2021)


CIS (Always High Grade)

As mentioned, CIS is always high grade and requires attentive management:

  • Typically treated with intravesical BCG

  • Close surveillance for response to treatment

  • Careful full bladder examination as CIS can be multifocal (present in multiple areas) (Poletajew et al., 2022)



Additional Factors in Your Report


Beyond stage and grade, your pathology report may mention other significant findings:


Lymphovascular Invasion

If present, this means cancer cells were found inside blood vessels or lymphatic channels. This finding may increase the risk of spread beyond the bladder (Mari et al., 2022).


Variant Histology

Sometimes bladder cancers show unusual cell patterns or types. Certain variants (like micropapillary, plasmacytoid, nested, or sarcomatoid) may influence treatment decisions due to their unique behavior (Humphrey et al., 2022).


Muscularis Propria Sampling

The report should mention whether muscle tissue was included in the sample. This is important to confirm the cancer hasn't invaded the muscle layer (which would make it muscle-invasive bladder cancer, a different disease category) (Cumberbatch et al., 2020).



Takeaway / Closing


Your stage and grade are the roadmap for your treatment plan. Understanding them helps you understand why your doctor recommends certain therapies and follow-ups. The combination of this information guides risk assessment, which directly determines:

  • How often you'll need follow-up cystoscopies

  • Whether you need additional treatments beyond surgery

  • What type of intravesical therapy might be most appropriate

  • Your long-term risk assessment (Babjuk et al., 2023)


Don't hesitate to ask your doctor to walk you through your specific report. Understanding your unique tumor characteristics empowers you to participate more actively in your care decisions and helps explain why certain approaches are recommended for your situation (Mason et al., 2022).



Call to Action


Did understanding your stage/grade help you feel more in control? Share your "aha!" moment in the comments below. If you found this information helpful, please share it with others who might benefit from clearer understanding of their NMIBC diagnosis.



References


Babjuk, M., Burger, M., Capoun, O., Cohen, D., Compérat, E. M., Dominguez Escrig, J. L., Gontero, P., Liedberg, F., Masson-Lecomte, A., Mostafid, A. H., Palou, J., van Rhijn, B. W. G., Rouprêt, M., Seisen, T., Soukup, V., Sylvester, R. J., & Zigeuner, R. (2023). European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2023 Update. European Urology, 83(2), 156-164.


Chang, S. S., Bochner, B. H., Chou, R., Dreicer, R., Kamat, A. M., Lerner, S. P., Lotan, Y., Meeks, J. J., Michalski, J. M., Morgan, T. M., Quale, D. Z., Skinene, J. E., Smith, N. D., Souter, L. H., & Svatek, R. S. (2022). Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Guideline Part I. Journal of Urology, 207(1), 23-34.


Compérat, E., Amin, M. B., Epstein, J. I., Hansel, D. E., Paner, G., Al-Ahmadie, H., Algaba, F., Aron, M., Berney, D. M., Billis, A., Brimo, F., Cheng, L., Cheville, J., Egevad, L., Evans, A., Fine, S. W., Grignon, D., Humphrey, P. A., Magi-Galluzzi, C., McKenney, J. K. (2023). The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Critical Biomarker Testing in Bladder Cancer. Advances in Anatomic Pathology, 30(1), 1-17.


Cumberbatch, M. G., Foerster, B., Catto, J. W., Kamat, A. M., Kassouf, W., Jubber, I., Shariat, S. F., Sylvester, R. J., & Gontero, P. (2020). Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. European Urology, 77(6), 925-933.


Ferro, M., Di Lorenzo, G., Buonerba, C., Terracciano, D., Lucarelli, G., Busetto, G. M., Autorino, R., & Crocetto, F. (2021). Predictors of residual T1 high grade on re-transurethral resection in a large multi-institutional cohort of patients with primary T1 high-grade/Grade 3 bladder cancer. Journal of Cancer Research and Clinical Oncology, 147(6), 1861-1868.


Humphrey, P. A., Moch, H., Cubilla, A. L., Ulbright, T. M., & Reuter, V. E. (2022). The 2022 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours. European Urology, 82(1), 115-127.


Kamat, A. M., Sylvester, R. J., Böhle, A., Palou, J., Lamm, D. L., Brausi, M., Soloway, M., Persad, R., Buckley, R., Colombel, M., & Witjes, J. A. (2021). Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. Journal of Clinical Oncology, 39(4), 361-370.

Knowles, M. A., & Hurst, C. D. (2022). Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nature Reviews Cancer, 22(2), 65-76.


Mari, A., Kimura, S., Foerster, B., Abufaraj, M., D'Andrea, D., Gust, K. M., Shariat, S. F. (2022). A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. BJU International, 129(5), 599-610.


Mason, S. J., Catto, J. W., Downing, A., Bottomley, S. E., Glaser, A. W., & Wright, P. (2022). Qualitative analysis of patient experiences of bladder cancer and their implications for practice. European Journal of Oncology Nursing, 57, 102101.


Patel, V. G., Oh, W. K., & Galsky, M. D. (2020). Treatment of muscle-invasive and advanced bladder cancer in 2020. CA: A Cancer Journal for Clinicians, 70(5), 404-423.


Poletajew, S., Zapała, P., Lemiński, A., Adamczyk, P., Świniarski, P., Walczak, R., Grzegółkowski, P., Radziszewski, P., & Puszynski, M. (2022). Carcinoma in situ of urinary bladder: a systematic review of current knowledge regarding detection, treatment, and outcomes. Cancer Management and Research, 14, 37-52.


Robertson, A. G., Groeneveld, C. S., Jordan, B., Lin, X., McLaughlin, K. A., Das, A., Fall, L. A., Fantini, D., Taxter, T. J., Mogil, L. S., Lindskrog, S. V., Dyrskjøt, L., McConkey, D. J., & Meeks, J. J. (2022). Identification of Differential Tumor Subtypes of T1 Bladder Cancer. European Urology, 81(1), 71-82.


Sylvester, R. J., Oosterlinck, W., Holmang, S., Sydes, M. R., Birtle, A., Gudjonsson, S., De Nunzio, C., Okamura, K., Kaasinen, E., Solsona, E., Ali-El-Dein, B., Tatar, C. A., Inman, B. A., N'Dow, J., Oddens, J. R., & Babjuk, M. (2020).


Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? European Urology, 79(4), 343-352.


Sylvester, R. J., Rodríguez, O., Hernández, V., Turturica, D., Bauerová, L., Bruins, H. M., Maclennan, S., Yuan, C. Y., N'Dow, J., & Witjes, J. A. (2021). European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. European Urology, 79(4), 480-488.



Disclaimer: This article is intended for informational purposes only and does not constitute medical advice. Always consult with your healthcare provider regarding your specific medical condition and treatment options.


Comentários

bottom of page